Trial reportJournal of the American Heart Association2019
Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low-Dose Prasugrel or Clopidogrel.
Trial report in Journal of the American Heart Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low-Dose Prasugrel or Clopidogrel.Journal of the American Heart Association · 2019Trial
- Treatment of non-ST-segment elevation myocardial infarction in the elderly: the SENIOR-RITA trial.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Ultrashort Versus 1-Year Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Meta-analysis of Randomized Controlled Trials.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Review
- Management of Acute Coronary Syndromes in Older People: Comprehensive Review and Multidisciplinary Practice-Based Recommendations.Journal of clinical medicine · 2024Review
- Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population.Current atherosclerosis reports · 2024Review
- Optimal anti-platelet therapy for older patients with acute coronary syndrome: a network meta-analysis of randomized trials comprising 59,284 older patients.Journal of thrombosis and thrombolysis · 2024Article
- De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis.Nature reviews. Cardiology · 2023Review
- Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy.Journal of thrombosis and thrombolysis · 2023Observational
- Antiplatelet Strategies for Older Patients with Acute Coronary Syndromes: Finding Directions in a Low-Evidence Field.Journal of clinical medicine · 2023Review
- Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association.Circulation · 2023Review
- Modulation of Glycoprotein VI and Its Downstream Signaling Pathways as an Antiplatelet Target.International journal of molecular sciences · 2022Review
- Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk.International journal of molecular sciences · 2021Review
- Coronary Heart Disease (CHD) in Elderly Patients: Which Drug to Choose, Ticagrelor and Clopidogrel? A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of cardiovascular development and disease · 2021Review
- Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome.Journal of geriatric cardiology : JGC · 2021Article
- Impact of genetic variants on clinical outcome after percutaneous coronary intervention in elderly patients.Aging · 2021Article
- Tailoring P2YJournal of the American Heart Association · 2019Article
- "No Such Thing as a Free Lunch": Personalized P2YJournal of the American Heart Association · 2019Article
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Elderly patients have high ischemic and bleeding rates after acute coronary syndrome; however, the occurrence of these complications over time has never been studied. This study sought to characterize average daily ischemic rates ( ADIRs ) and average daily bleeding rates ( ADBRs ) over 1 year in patients aged >74 years with acute coronary syndrome undergoing percutaneous coronary intervention who were randomized in the Elderly ACS 2 trial, comparing low-dose prasugrel (5 mg daily) with clopidogrel (75 mg daily). Methods and Results ADIRs and ADBRs were calculated as the total number of events, including recurrent events, divided by the number of patient-days of follow-up and assessed within different clinical phases: acute (0-3 days), subacute (4-30 days), and late (31-365 days). Generalized estimating equations were used to test the least squares mean differences for the pairwise comparisons of ADIRs and ADBRs and the pairwise comparison of clopidogrel versus prasugrel effects. Globally, ADIRs were 2.6 times (95% CI, 2.4-2.9) higher than ADBRs . ADIRs were significantly higher in the clopidogrel arm than in the low-dose prasugrel arm in the subacute phase ( P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.